๐ด๐ด Mark your calendars!!! ๐๏ธ January 21-23 will put Padova in the spotlight โจ
๐ธ Wirsung 2027 ๐ค Punkreas Revolution!
๐ A stellar International faculty including the one and only @DeMadaria ๐ช๐ธ
๐ค and a full session on tele surgery of the pancreasโฆ
๐คณ Scan the code!
๐ธ๐ฌ What a week at #IHPBA2026 in Singapore!
Grateful for the opportunity to share our research and connect with the amazing international HPB community.
Great science, inspiring people, exciting collaborations, and unforgettable moments with my ๐ฎ๐น & ๐ณ๐ฑ families!
โ Discontinuing surveillance of Trivial IPMN is safe! Out in @UEGJournal
๐ 25% would be discharged / No HGD missed!
๐ธ Money saved depend on local health care system
๐ Prospective evaluation ongoing with @MarcBesselink@DeMadaria and others ๐๐ผโโ๏ธ
https://t.co/edc1TSK2wn
What do we mean with "recurrence" of IPMN ๐ after surgery ?!
โ๏ธ word - โ๏ธ different scenario
๐ IPMN after resection of non-invasive are "de novo" in 50% cases
๐ฆ Recurrence of invasive IPMN was 42%, most systemic if ๐ node + and tubular type
https://t.co/IgxtRGW9hZ
Grateful to have completed the P2000 course of the @EurPancClub@YouppiePancreas ๐ช๐ป๐ฅ
๐A TRULY outstanding experience!!!
๐ซฑ๐ปโ๐ซฒ๐ผ This is not the end, but itโs the beginning of long-lasting collaboration and friendship!
โจA special thanks to my mentors @Gio_Marchegiani@LMaggino
A pleasure to welcome Prof. Kuirong Jiang and Dr. Zipeng Lu from Nanjing ๐จ๐ณ, a highly renowned center for pancreatic surgery, to Padova.
Valuable scientific exchange in the operating room ๐ฅโ and equally enjoyable moments shared beyond it ๐๐ซฑ๐ปโ๐ซฒ๐ผ
๐ค Whatโs better than a lecture by @BasGrootKoerkam on neoadjuvant treatment for pancreas cancer?!
๐โโ๏ธ probably such a lecture delivered at your own Institution!!!
๐ Thank you Bas for such a Christmas ๐ gift and already looking forward to the results of Preopancโฆ
Our delegation from Padova took part in the 4th AICEP Congress in Rome, alongside leading experts in hepatobiliary and pancreatic surgery and liver transplantation.
Grateful for the opportunity to present our work.
It was also a true honor to meet Professor Henri Bismuth.
๐ฃ Pancreas surgeons! This survey promoted by our PG course #Pancreas2000 is calling by your name!
๐ง How do you deal with vascular resections for pancreas cancer?!
5 min! ๐ and infinite gratitude ๐
https://t.co/e8IEd9wuN3
๐ Pancreas2000 is the official postgraduate course of the EPC @my_ueg ๐ต๐ต
๐ฉบ Almost 2 years / 5 in person meetings / countless chances for mutual exchange and education in pancreatology
๐ซต The applications for the 2026 course will open this fall! Join us!
What is "Conversion surgery" ๐โก๏ธ๐ฆ for upfront unresectable upper GI and HPB cancers โ๏ธ
๐ Triggered by improvements in non surgical therapies ๐งฐ Many techniques included
๐ Able to improve survival!
๐ก All u need to know in โฌ comprehensive review
https://t.co/3rABt0KMk1
Grateful and excited to be starting my PhD journey at @ErasmusMC Rotterdam ๐ณ๐ฑ in a joint program with @UniPadova ๐ฎ๐นCanโt wait to see where this new chapter will take me!
A huge thank you to @BasGrootKoerkam and @Gio_Marchegiani for this opportunity
What a great start at the @EAHPBA in Dublin!
Discussion of major hot topics :
๐ Need for Redefining the concept of resectability in pancreatic surgery
๐ Role and effectiveness of neoadjuvant therapy
๐ช Outcomes of minimally invasive surgery
๐จ FOLFIRINOX vs. GEM Nab Paclitaxel for LAPC
๐ 171 pts median PFS 9 months better in FOLFIRINOX group
๐ฏ FOLFIRINOX improves PFS significantly compared with gemcitabine and is well tolerated in LAPC
๐ฅhttps://t.co/TJdRlaF7S2
We warmly ๐ค welcome dr. Aya Maekawa ๐ฏ๐ต from the Cancer Institute Hospital of Tokyo to our team for her fellowship ๐ฉบ
Thank you for being with us andโฆ Welcome to ๐ดโช๏ธ @UniPadova !!!
๐ต Pancreas2000 is the young talent group of the @EurPancClub and is aimed at shaping the nextgen of pancreas experts
๐ I feel very privileged to coordinate this program, our future is in good hands! ๐
๐๏ธ Bordeline observable IPMNs ๐๏ธ
โ๏ธ Reappraisal of the actual benefit of extended surveillance between cancer risk ๐ซธ๐ซท discontinuation
๐งฌ "Less invasive" biomarkers are expected to exclude from FU harmless cyst since first observation
๐ https://t.co/CvAGjbqXMK
Can we personalize ๐ surveillance of IPMN?!
๐ฎ๐น ๐บ๐ธ ๐ฉ๐ช ๐ฐ๐ท ๐ณ๐ฑ ๐ฌ๐ง ๐ธ๐ฌ ๐ช๐ธ analysis of 2k IPMN developing WF/HRS
๐ด Age and ๐ซง cyst size impact the timing of surveillance
๐ฆ First prudential control always 6 monthsโฆ then ๐ฆ๐ฆ 2 years if no WF/HRS
๐https://t.co/w47mqUTTNw